SEP 24, 2018 7:56 PM PDT

Pain Management Drug Found Ineffective in Traumatic Injury Patients

WRITTEN BY: Nouran Amin

Image via Scientific American

Driven by the effort to identify effective non-opioid pain medications, a recent international research study with a publication in the Journal Neurology, found that the drug ‘pregabalin’ is not effective in treating chronic pain associated with traumatic nerve injury. "The unrelenting burning or stabbing symptoms due to nerve trauma are a leading reason why people seek treatment for chronic pain after a fall, car accident, or surgery," explains John Markman, M.D., director of the Translational Pain Research Program in the University of Rochester Department of Neurosurgery and lead author of the study. "While these finding show that pregabalin is not effective in controlling the long-term pain for traumatic injury, it may provide relief for patients experience post-surgical pain."

Watch Video Below To Learn More About Traumatic Brain Injury:

Marketed under Pfizer, Pregabalin is under the name Lyrica and is approved to treat chronic pain associated with shingles, spinal cord injury, fibromyalgia, and diabetic peripheral neuropathy. But, is commonly a prescription drug for treating chronic nerve injury syndromes that occur after motor vehicle accidents, falls, sports injuries, knee or hip replacement and as well as surgeries that include hernia repair or mastectomy. Previously, an eight-week study showed that pregabalin decreased pain intensity better than placebo in chronic, post-traumatic pain syndromes. The findings resulted in many doctors to prescribe pregabalin for long-term pain that takes a while to resolve.

The present study, consisting of a retrospective analysis, found that pregabalin did not hold high efficacy for pain management in individuals with traumatic nerve injury. "The possibility that there was pain relief for those patients who had a hernia repair, or breast surgery for cancer, or a joint replacement lays the groundwork for future studies in these post-surgical syndromes where there is so much need for non-opioid treatments," says Markman. "Given the rising rates of surgery and shrinking reliance on opioids, it is critical that we understand how to study new drugs that work differently in patients like the ones included in this study.”

Source: University of Rochester Medical Center

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 13, 2020
Drug Discovery & Development
Russia Completes First Human Trial for COVID-19 Vaccine
JUL 13, 2020
Russia Completes First Human Trial for COVID-19 Vaccine
The Sechenov University Center for Clinical Research in Moscow, Russia, has completed its first round of clinical trials ...
JUL 17, 2020
Immunology
More Potential Antibody Therapies for COVID Emerge
JUL 17, 2020
More Potential Antibody Therapies for COVID Emerge
When it comes to clinical countermeasures against COVID-19, one class of molecules stands out among the others: antibodi ...
JUL 19, 2020
Drug Discovery & Development
Study Finds Turmeric has Antiviral Effects
JUL 19, 2020
Study Finds Turmeric has Antiviral Effects
Researchers from the Wuhan University of Engineering in China have found that curcumin, a natural compound found in turm ...
JUL 25, 2020
Drug Discovery & Development
New Method for Targeting The Herpes Virus
JUL 25, 2020
New Method for Targeting The Herpes Virus
A new way for treating the human herpes viruses was recently discovered by researchers at Lund University in Sweden. The ...
JUL 29, 2020
Drug Discovery & Development
Will We Have a COVID-19 Vaccine by Year-End?
JUL 29, 2020
Will We Have a COVID-19 Vaccine by Year-End?
This week, pharmaceutical companies Moderna and Pfizer launched giant Phase III 30,000-subject trials for their COVID-19 ...
AUG 04, 2020
Drug Discovery & Development
Erectile Dysfunction Drug Cures Critical COVID-19 Patients
AUG 04, 2020
Erectile Dysfunction Drug Cures Critical COVID-19 Patients
Critically ill patients who received COVID-19 drug candidate aviptadil (RLF-100) were able to make a rapid recovery from ...
Loading Comments...